Shots:
- Lilly‘s P-III trial assessed orforglipron vs PBO in maintaining weight loss in 376 adults with obesity/overweight & weight-related comorbidities who previously completed the initial treatment with Wegovy/Zepbound in the SURMOUNT-5 trial; NDA was submitted to FDA & received a US FDA’s CNPV
- Trial met its 1EP in SURMOUNT-5 pts at a weight plateau, showing superior weight-loss maintenance with 52wk. differences of 0.9kg & 5kg after switching from Wegovy & Zepbound, respectively (efficacy estimand)
- In post-hoc 24wk. analyses, weight change from ATTAIN-MAINTAIN baseline was −0.1kg vs +9.4kg (PBO) after switching from Wegovy & +2.6kg vs +9.1kg (PBO) from Zepbound; mean weight was 113.5 & 115.8kg at SURMOUNT-5 start, 95 & 90.9kg at oral switch, & 95.9kg in both groups after 52wks.
Ref: Eli Lilly| Image: Eli Lilly| Press Release
Related News: Eli Lilly Reports P-III (TRIUMPH-4) Trial Data on Retatrutide for Weight Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
